Related Experiment Video
Updated: Apr 19, 2026
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
Published on: August 1, 2025
Asparaginase in acute lymphoblastic leukemia
Jitesh D Kawedia1, Michael E Rytting2
1Department of Pharmacy Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
Insights
Pediatric acute lymphoblastic leukemia survival has improved, but adult outcomes lag. This review explores optimizing asparaginase therapy through monitoring to enhance adult cancer treatment efficacy and reduce side effects.
Area of Science:
- Oncology
- Pediatric Hematology
- Pharmacology
Background:
- Pediatric acute lymphoblastic leukemia (ALL) cure rates exceed 90%, a significant improvement over recent decades.
- Adult and adolescent ALL survival rates have not mirrored pediatric advancements, despite similar complete remission rates.
- Asparaginase is a cornerstone of pediatric ALL therapy, contributing to improved outcomes.
Purpose of the Study:
- To review the role of asparaginase in acute lymphoblastic leukemia treatment.
- To explore strategies for optimizing asparaginase use in adult patients.
- To investigate the potential of therapeutic drug monitoring to improve asparaginase efficacy and safety.
Main Methods:
- Literature review focusing on asparaginase in pediatric and adult ALL.
- Analysis of treatment regimens and outcomes.
- Discussion of therapeutic drug monitoring principles and applications.
Main Results:
- Asparaginase is crucial for pediatric ALL cure rates.
- Differences in treatment intensity and drug exposure may explain outcome disparities between pediatric and adult ALL.
- Therapeutic drug monitoring can guide asparaginase dosing to maximize efficacy and minimize toxicity.
Conclusions:
- Optimizing asparaginase administration, potentially through monitoring, is essential for improving adult ALL treatment outcomes.
- Further research into asparaginase pharmacokinetics and pharmacodynamics in adults is warranted.
- Personalized asparaginase therapy could bridge the survival gap in adult acute lymphoblastic leukemia.
Abstract:
Cure rates in pediatric acute lymphoblastic leukemia have significantly improved over the past decades. Now, almost 90% of children will survive the disease. The cure rates in adolescents, young adults, and adults have not kept pace with the improvements in younger patients, even though almost an equal proportion of adult patients achieve complete remission as their pediatric counterparts. Differences in treatment regimens might be important. Intensive use of asparaginase has been a key component of successful pediatric therapy. In this review, we focus on the use of asparaginase and the potential of optimizing asparaginase use via monitoring to minimize adverse drug events and improve efficacy of the drug.
